Clinical Trials Logo

Nonalcoholic Steatohepatitis clinical trials

View clinical trials related to Nonalcoholic Steatohepatitis.

Filter by:

NCT ID: NCT03861819 Completed - Liver Diseases Clinical Trials

Feasibility of VIIT in Adults With NASH

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether patients with stage 1-3 NASH-related fibrosis are able to complete a single vigorous-intensity interval training (VIIT) session on an indoor rowing machine and provide blood samples before and afterwards. The results of this study will provide the foundation for future research on the role of VIIT in treating NASH.

NCT ID: NCT03723252 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Dapagliflozin Efficacy and Action in NASH

DEAN
Start date: March 20, 2019
Phase: Phase 3
Study type: Interventional

This is a multicentre, randomized, placebo-controlled trial to assess the efficacy and safety of dapagliflozin on improving non-alcoholic steatohepatitis as determined by liver biopsies and metabolic risk factors.

NCT ID: NCT03683589 Completed - Clinical trials for Bariatric Surgery Candidate

De Novo Lipogenesis in Severity of NAFLD

Start date: February 1, 2019
Phase:
Study type: Observational

NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Previous studies has shown that elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFLD from equally-obese subjects with low IHTG. The purpose of this study is to directly by measure DNL in human liver tissue and comparing it to liver histological scores from patient biopsies.

NCT ID: NCT03674476 Completed - NAFLD Clinical Trials

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

Start date: September 11, 2018
Phase: Phase 1
Study type: Interventional

This is an investigational study to evaluate the experimental medication BMS-986036 in participants with different levels of kidney function.

NCT ID: NCT03656744 Completed - NAFLD Clinical Trials

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Start date: November 26, 2018
Phase: Phase 2
Study type: Interventional

Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.

NCT ID: NCT03486912 Completed - Liver Fibrosis Clinical Trials

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

FALCON 2
Start date: June 12, 2018
Phase: Phase 2
Study type: Interventional

This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage characterized by normal liver tissue being replaced by scar tissue).

NCT ID: NCT03486899 Completed - Liver Fibrosis Clinical Trials

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

FALCON 1
Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).

NCT ID: NCT03449446 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

ATLAS
Start date: March 21, 2018
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are: - To assess the safety and tolerability of selonsertib (SEL), firsocostat (FIR) and cilofexor (CILO), administered alone or in combination, in participants with bridging fibrosis or compensated cirrhosis due to NASH - To evaluate changes in liver fibrosis, without worsening of NASH

NCT ID: NCT03445208 Completed - Liver Fibrosis Clinical Trials

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Start date: February 14, 2018
Phase: Phase 1
Study type: Interventional

This is a study of experimental medication BMS-986036 given to healthy participants.

NCT ID: NCT03439254 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

REVERSE
Start date: August 30, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.